

# PRODUCT INFORMATION




**PD 173074**

Item No. 13032

**CAS Registry No.:** 219580-11-7  
**Formal Name:** N-[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea

**MF:** C<sub>28</sub>H<sub>41</sub>N<sub>7</sub>O<sub>3</sub>  
**FW:** 523.7  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 238, 284, 368 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

PD 173074 is supplied as a crystalline solid. A stock solution may be made by dissolving the PD 173074 in the solvent of choice. PD 173074 is soluble in the organic solvent DMSO, which should be purged with an inert gas, at a concentration of approximately 10 mg/ml.

## Description

The fibroblast growth factor receptors (FGFRs) are cell surface receptors with intrinsic tyrosine kinase activity, which is necessary for receptor activation and signal propagation. PD 173074 is a potent and selective inhibitor of FGFR tyrosine kinase activity, blocking autophosphorylation of FGFR1 with an IC<sub>50</sub> value of 21.5 nM.<sup>1</sup> For comparison, it weakly inhibits PDGFR and c-Src (IC<sub>50</sub> = 17.6 and 19.8 μM, respectively) and has no effect on EGFR, InsR, MEK, or PKC.<sup>1</sup> PD 173074 also prevents signaling, at nanomolar levels, through FGFR2-5.<sup>2-6</sup> Inhibition of FGFR signaling using PD 173074, impairs angiogenesis as well as self-renewal of stem cells via ERK1/2 activation.<sup>2,5-8</sup>

## References

1. Mohammadi, M., Froum, S., Hamby, J.M., et al. *EMBO J.* **17(20)**, 5896-5904 (1998).
2. Skaper, S.D., Kee, W.J., Facci, L., et al. *J. Neurochem.* **75(4)**, 1520-1527 (2000).
3. Koziczak, M., Holbro, T., and Hynes, N.E. *Oncogene* **23(20)**, 3501-3508 (2004).
4. Grand, E.K., Chase, A.J., Heath, C., et al. *Leukemia* **18(5)**, 962-966 (2004).
5. St. Bernard, R., Zheng, L., Liu, W., et al. *Endocrinology* **146(3)**, 1145-1153 (2005).
6. Stavridis, M.P., Lunn, J.S., Collins, B.J., et al. *Development* **134(16)**, 2889-2894 (2007).
7. Kunath, T., Saba-El-Leil, M.K., Almousailleakh, M., et al. *Development* **134(16)**, 2895-2902 (2007).
8. Zaragosi, L.E., Ailhaud, G., and Dani, C. *Stem Cells* **24(11)**, 2412-2419 (2006).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2018

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM